Grace Therapeutics Amends 10-Q for Share Count Correction

TL;DR

**Grace Therapeutics' 10-Q/A is a non-event, just a clerical fix for outstanding shares; no material impact on the stock.**

AI Summary

Grace Therapeutics, Inc. (GRCE) filed a Form 10-Q/A on November 17, 2025, solely to amend the number of outstanding common shares on its cover page for the quarter ended September 30, 2025. The corrected number of outstanding shares of common stock as of November 13, 2025, is 15,474,026. This amendment does not introduce any changes to the financial statements, revenue figures, or net income previously reported in the original Form 10-Q filed on November 13, 2025. The filing explicitly states that no other updates were made to reflect events subsequent to the original filing date. New certifications from the Chief Executive Officer, Prashant Kohli, and Principal Financial Officer, Robert DelAversano, were included as exhibits, as required by Rule 12b-15 of the Securities Exchange Act of 1934. The company's strategic outlook, key business changes, and risks remain as outlined in the original November 13, 2025, 10-Q, as this amendment is purely administrative.

Why It Matters

This 10-Q/A filing from Grace Therapeutics is a minor administrative correction, primarily impacting the accuracy of the public record regarding the company's outstanding share count, now at 15,474,026 shares as of November 13, 2025. For investors, this ensures precise calculations for per-share metrics like EPS or market capitalization, though it doesn't signal any operational or financial shifts. Employees and customers are largely unaffected, as the core business operations and financial health remain as previously disclosed. In a competitive biotech landscape, maintaining accurate regulatory filings is crucial for transparency and investor confidence, even for seemingly small adjustments.

Risk Assessment

Risk Level: low — The risk level is low because this 10-Q/A is explicitly filed "solely to correct the number of shares of common stock outstanding on the cover page" and states "No other changes have been made to the Original Filing." This indicates no new financial, operational, or strategic risks have emerged since the original November 13, 2025, 10-Q.

Analyst Insight

Investors should view this 10-Q/A as a non-material administrative update. No immediate action is required based on this filing alone, as it does not alter Grace Therapeutics' financial performance or outlook. Focus should remain on the substantive information from the original 10-Q filed on November 13, 2025.

Executive Compensation

Key Numbers

• 15,474,026 — Outstanding shares of common stock (Corrected number as of November 13, 2025, on the cover page)
• $0.0001 — Par value per share (Common stock par value)
• November 17, 2025 — Filing date of 10-Q/A (Date the amendment was filed)
• September 30, 2025 — Quarterly period ended (Period for which the original 10-Q was filed)
• November 13, 2025 — Original 10-Q filing date (Date the unamended 10-Q was filed)

Key Players & Entities

• Grace Therapeutics, Inc. (company) — Registrant filing the 10-Q/A
• Prashant Kohli (person) — Chief Executive Officer and Principal Executive Officer
• Robert DelAversano (person) — Principal Financial Officer
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market (company) — Exchange where GRCE Common Stock is registered
• State of Delaware (regulator) — Jurisdiction of incorporation for Grace Therapeutics, Inc.
• Amresh Kumar (person) — Party to a Letter Agreement dated November 12, 2025
• Carrie D'Andrea (person) — Party to a Letter Agreement dated November 12, 2025
• R. Loch Macdonald (person) — Party to a Letter Agreement dated November 12, 2025

FAQ

Industry Context

Grace Therapeutics, Inc. operates within the biotechnology and pharmaceutical sector, a highly competitive and innovation-driven industry. Companies in this space focus on research and development of novel therapeutics, often facing long development cycles, significant regulatory hurdles, and the need for substantial capital investment. The industry is characterized by rapid scientific advancements, patent cliffs, and strategic partnerships or acquisitions to advance drug pipelines.

Regulatory Implications

This filing is purely administrative and does not introduce new regulatory risks or compliance issues. The amendment adheres to SEC Rule 12b-15, ensuring proper disclosure of the corrected share count and updated executive certifications. The company's ongoing compliance with FDA and other health authority regulations remains a critical factor for its operational success.

What Investors Should Do

1. Review original Form 10-Q for financial and operational details.
2. Note the corrected outstanding share count.
3. Acknowledge the administrative nature of the filing.

Key Dates

• 2025-11-17: Filing of Form 10-Q/A (Amendment No. 1) — Corrected the number of outstanding common shares on the cover page. This is a purely administrative amendment.
• 2025-11-13: Original Form 10-Q filing for the quarter ended September 30, 2025 — This was the initial filing of the quarterly report, which is now being amended for a minor cover page correction.
• 2025-09-30: Quarterly period ended — The financial period covered by the original 10-Q filing.
• 2025-11-13: Outstanding shares of common stock as of this date — The corrected number of 15,474,026 shares is as of this date, as stated on the cover page of the amendment.

Glossary

10-Q/A

An amended quarterly report filed with the SEC to correct or supplement information previously filed in a Form 10-Q. (This filing is an amendment to a previous 10-Q, specifically to correct the number of outstanding shares.)

Rule 12b-15

SEC rule requiring new certifications from principal executive and financial officers when a Form 10-Q is amended. (This rule necessitated the inclusion of new certifications from the CEO and CFO in this amendment.)

Common Stock, par value $0.0001 per share

The basic class of stock representing ownership in Grace Therapeutics, Inc., with a nominal par value. (The number of these shares outstanding was the sole reason for this amendment filing.)

Sarbanes-Oxley Act of 2002 (SOX)

Federal law that mandates certain practices in financial and accounting information disclosure and transparency. (While SOX Section 906 certifications were included in the original 10-Q, they were not re-filed here as no financial statements were amended.)

Year-Over-Year Comparison

This Form 10-Q/A is an amendment to the original Form 10-Q filed on November 13, 2025. The amendment solely corrects the number of outstanding common shares on the cover page to 15,474,026 as of November 13, 2025. No financial statements, revenue figures, net income, or other substantive disclosures from the original filing have been altered. Therefore, there are no year-over-year comparisons or changes in key metrics to report from this specific amendment.

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share GRCE Nasdaq Stock Market
• $0 — the registrant, par value per share of $0.0001, as of November 13, 2025, was 15,4

Filing Documents

• ef20059408_10qa.htm (10-Q/A) — 51KB
• ef20059408_ex31-1.htm (EX-31.1) — 4KB
• ef20059408_ex31-2.htm (EX-31.2) — 4KB
• 0001140361-25-042491.txt ( ) — 211KB
• grce-20250930.xsd (EX-101.SCH) — 3KB
• grce-20250930_lab.xml (EX-101.LAB) — 27KB
• grce-20250930_pre.xml (EX-101.PRE) — 14KB
• ef20059408_10qa_htm.xml (XML) — 5KB

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: November 17, 2025 GRACE THERAPEUTICS, INC. By: /s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer (Principal Executive Officer) By: /s/ Robert DelAversano Name: Robert DelAversano Title: Principal Financial Officer (Principal Financial Officer)

View Full Filing

View this 10-Q/A filing on SEC EDGAR